Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. (Q37109227)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

review article

1 reference

title

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Paolo Lunghi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

James A. McCubrey

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

L S Steelman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

S L Abrams

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

J Whelan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

F E Bertrand

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

D E Ludwig

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

J Bäsecke

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

F Stivala

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

M Milella

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

A Tafuri

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

A Bonati

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

A M Martelli

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

publication date

13 March 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

686-707

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337767%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2008.26

4 January 2020

exact match

0 references

cites work

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

AKT/PKB signaling mechanisms in cancer and chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Identification of a viability domain in the granulocyte/macrophage colony-stimulating factor receptor beta-chain involving tyrosine-750

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Signaling domains of the beta c chain of the GM-CSF/IL-3/IL-5 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The complexity of PTEN: mutation, marker and potential target for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Regulation of cell death protease caspase-9 by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Transcriptional regulation by MAP kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Serine/threonine phosphorylation in cytokine signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Lack of Elk-1 phosphorylation and dysregulation of the extracellular regulated kinase signaling pathway in senescent human fibroblast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Biochemical and biological functions of the N-terminal, noncatalytic domain of extracellular signal-regulated kinase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Transient and sustained ERK phosphorylation and nuclear translocation in growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Activation of the granulocyte-macrophage colony-stimulating factor promoter in T cells requires cooperative binding of Elf-1 and AP-1 transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Interleukin-7: from bench to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Raf and the road to cell survival: a tale of bad spells, ring bearers and detours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Role of Bim in the survival pathway induced by Raf in epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The groove between the alpha- and beta-subunits of hormones with lutropin (LH) activity appears to contact the LH receptor, and its conformation is changed during hormone binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The iSH2 domain of PI 3-kinase is a rigid tether for p110 and not a conformational switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Intranuclear 3'-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Nuclear inositide signaling: an appraisal of phospholipase C beta 1 behavior in myelodysplastic and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Oncogenic PI3K and its role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Phosphoinositide 3-kinases as drug targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Interleukin 3-dependent survival by the Akt protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Transforming growth factor-beta1 stimulated protein kinase B serine-473 and focal adhesion kinase tyrosine phosphorylation dependent on cell adhesion in human hepatocellular carcinoma SMMC-7721 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The role of integrin-linked kinase (ILK) in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

ILKAP regulates ILK signaling and inhibits anchorage-independent growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

PIKE/nuclear PI 3-kinase signaling in preventing programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The Akt-mTOR tango and its relevance to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Novel targets of Akt, p21(Cipl/WAF1), and MDM2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Participation of the calcium/calmodulin-dependent kinases in hydrogen peroxide-induced Ikappa B phosphorylation in human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Redox regulation of the calcium/calmodulin-dependent protein kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

CREB is a regulatory target for the protein kinase Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Constitutive activation of S6 kinase by deletion of amino-terminal autoinhibitory and rapamycin sensitivity domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

p70 S6 kinase is regulated by protein kinase Czeta and participates in a phosphoinositide 3-kinase-regulated signalling complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

p70s6 kinase is a functional target of insulin activated Akt cell-survival signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Regulation of cell migration by the C2 domain of the tumor suppressor PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Multiple forms of an inositol polyphosphate 5-phosphatase form signaling complexes with Shc and Grb2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

p150Ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Distribution of the src-homology-2-domain-containing inositol 5-phosphatase SHIP-2 in both non-haemopoietic and haemopoietic cells and possible involvement of SHIP-2 in negative signalling of B-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The protooncogene TCL1 is an Akt kinase coactivator

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Identification of the TCL1 gene involved in T-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Tcl1 enhances Akt kinase activity and mediates its nuclear translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Structural basis for the co-activation of protein kinase B by T-cell leukemia-1 (TCL1) family proto-oncoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

A modeled hydrophobic domain on the TCL1 oncoprotein mediates association with AKT at the cytoplasmic membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Mammalian target of rapamycin as a therapeutic target in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

mTOR integrates amino acid- and energy-sensing pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

TOR regulates ribosomal protein gene expression via PKA and the Forkhead transcription factor FHL1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Survival of acute myeloid leukemia cells requires PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

ERK implication in cell cycle regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

SOCS proteins: negative regulators of cytokine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Jak2 is essential for signaling through a variety of cytokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Evolutionary analysis for functional divergence of Jak protein kinase domains and tissue-specific genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Jak2-Stat5 interactions analyzed in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Genomic sequence, organization, and chromosomal localization of human JAK3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Developmental defects of lymphoid cells in Jak3 kinase-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The role of Jak3 in lymphoid development, activation, and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha/beta and for signal transduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/Signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Jak-STAT signaling induced by the v-abl oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

JAK-STAT signaling activated by Abl oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Cloning and characterization of novel CIS family genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Twenty proteins containing a C-terminal SOCS box form five structural classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

A new protein containing an SH2 domain that inhibits JAK kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Structure and function of a new STAT-induced STAT inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

A family of cytokine-inducible inhibitors of signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The suppressors of cytokine signalling (SOCS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

SOCS1 deficiency results in accelerated mammary gland development and rescues lactation in prolactin receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Phosphorylation and regulation of Raf by Akt (protein kinase B)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Serum- and glucocorticoid-inducible kinase SGK phosphorylates and negatively regulates B-Raf

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Synergistic effects of pi3k/akt on abrogation of cytokine-dependency induced by oncogenic raf.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Transformation of interleukin-3-dependent cells without participation of Stat5/bcl-xL: cooperation of akt with raf/erk leads to p65 nuclear factor kappaB-mediated antiapoptosis involving c-IAP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element-binding protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Definitive hematopoiesis requires the mixed-lineage leukemia gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Inducer-and cell type-specific regulation of antiapoptotic MCL1 in myeloid leukemia and multiple myeloma cells exposed to differentiation-inducing or microtubule-disrupting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The transcriptional targets of p53 in apoptosis control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Guilty as charged: B-RAF is a human oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

B- and C-RAF display essential differences in their binding to Ras: the isotype-specific N terminus of B-RAF facilitates Ras binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Regulation and role of Raf-1/B-Raf heterodimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

RAF/RAS oncogenes and mismatch-repair status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Absence of BRAF gene mutation in non-melanoma skin tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Phosphatidylinositol-3-OH kinase as a direct target of Ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Downstream effectors of oncogenic ras in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidylinositol 3-kinase, Cdc42/Rac and Pak

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

K-Ras and H-Ras activation promote distinct consequences on endometrial cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Ubiquitination regulates PTEN nuclear import and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Essential role for nuclear PTEN in maintaining chromosomal integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Patterns of somatic mutation in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

AKT activation predicts outcome in breast cancer patients treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

FLT3 mutations in acute myeloid leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Genomic acute myeloid leukemia-associated inv(16)(p13q22) breakpoints are tightly clustered.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Oncogenic transcription factors in the human acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Characterization of a recurrent translocation t(2;3)(p15-22;q26) occurring in acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Myeloid differentiation antigen and cytokine receptor expression on acute myelocytic leukaemia cells with t(16;21)(p11;q22): frequent expression of CD56 and interleukin-2 receptor alpha chain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Unusual type of TLS/FUS-ERG chimeric transcript in a pediatric acute myelocytic leukemia with 47,XX,+10,t(16;21)(p11;q22).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

NUP98 fusion in human leukemia: dysregulation of the nuclear pore and homeodomain proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogénétique Hématologique.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Mll rearrangements in haematological malignancies: lessons from clinical and biological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Efficient and easy detection of MLL-AF4, MLL-AF9 and MLL-ENL fusion gene transcripts by multiplex real-time quantitative RT-PCR in TaqMan and LightCycler.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Fusion tyrosine kinase mediated signalling pathways in the transformation of haematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Chronic myeloproliferative disorders: a tyrosine kinase tale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

A microelectronic DNA chip detects the V617F JAK-2 mutation in myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

t(5;12)(q23-31;p13) with ETV6-ACSL6 gene fusion in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

JAK2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E and CFU-GM) in essential thrombocythemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

The JAK2 V617F mutation is rare in RARS but common in RARS-T

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

Ras-dependent growth factor regulation of MEK kinase in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

A membrane proximal domain of the human interleukin-3 receptor beta c subunit that signals DNA synthesis in NIH 3T3 cells specifically binds a complex of Src and Janus family tyrosine kinases and phosphatidylinositol 3-kinase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Proto-oncogene TCL1: more than just a coactivator for Akt

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

AKT plays a central role in tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Nuclear factor-kappaB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Genomic organization of human JAK2 and mutation analysis of its JH2-domain in leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Defective lymphoid development in mice lacking Jak3

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Equitable Allocation of Antiretrovirals in Resource-Constrained Countries

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Allelic losses and genetic instabilities of PTEN and p73 in non-Hodgkin lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Overexpression of phosphatidylinositol 3-kinase in human lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Tyrosine phosphorylation of the p85 subunit of phosphatidylinositol 3-kinase correlates with high proliferation rates in sublines derived from the Jurkat leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Clonotypic analysis of acute lymphoblastic leukemia with a double TEL-AML1 fusion at onset and relapse

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Quantification of minimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real-time PCR assay

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Molecular biology of Burkitt's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Inhibition of myc promoter and telomerase activity and induction of delayed apoptosis by SYUIQ-5, a novel G-quadruplex interactive agent in leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Expression of the JAK2 V617F mutation is not found in de novo AML and MDS but is detected in MDS-derived leukemia of megakaryoblastic nature

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

JAK2 V617F due to a novel TG --> CT mutation at nucleotides 1848-1849: diagnostic implication

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Screening of JAK2 V617F mutation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

JAK2 mutation in a boy with polycythemia vera, but not in other pediatric hematologic Disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

The lack of association between JAK2 V617F mutation and myelodysplastic syndrome with or without myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Activating mutations of JAK2V617F are uncommon in t-MDS and t-AML and are only observed in atypic cases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021

The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.26

7 January 2021